Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 2
1993 1
1997 1
2009 2
2014 1
2016 1
2017 2
2018 1
2019 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Transcriptome-based network analysis reveals a spectrum model of human macrophage activation.
Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL. Xue J, et al. Among authors: emde m. Immunity. 2014 Feb 20;40(2):274-88. doi: 10.1016/j.immuni.2014.01.006. Epub 2014 Feb 13. Immunity. 2014. PMID: 24530056 Free PMC article.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD. Seckinger A, et al. Among authors: emde m. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2. Cancer Cell. 2017. PMID: 28262554 Free article.
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A. Hose D, et al. Among authors: emde m. J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5. J Hematol Oncol. 2019. PMID: 31242924 Free PMC article. Clinical Trial.
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D. Seckinger A, et al. Among authors: emde m. Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018. Front Immunol. 2018. PMID: 30079070 Free PMC article.
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.
Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D. Schmitt M, et al. Among authors: emde m. Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17. Oncotarget. 2016. PMID: 29156688 Free PMC article.
A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
Bautsch W, Kretzschmar T, Stühmer T, Kola A, Emde M, Köhl J, Klos A, Bitter-Suermann D. Bautsch W, et al. Among authors: emde m. Biochem J. 1992 Nov 15;288 ( Pt 1)(Pt 1):261-6. doi: 10.1042/bj2880261. Biochem J. 1992. PMID: 1445269 Free PMC article.
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page